NASDAQ:VXRT Vaxart (VXRT) Stock Price, News & Analysis $0.71 -0.01 (-1.38%) (As of 11/13/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Vaxart Stock (NASDAQ:VXRT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vaxart alerts:Sign Up Key Stats Today's Range$0.69▼$0.7550-Day Range$0.69▼$0.9952-Week Range$0.52▼$1.54Volume1.46 million shsAverage Volume2.49 million shsMarket Capitalization$126.74 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingBuy Company OverviewVaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.Read More… New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Vaxart Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks45th Percentile Overall ScoreVXRT MarketRank™: Vaxart scored higher than 45% of companies evaluated by MarketBeat, and ranked 699th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingVaxart has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVaxart has only been the subject of 1 research reports in the past 90 days.Read more about Vaxart's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vaxart are expected to grow in the coming year, from ($0.47) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxart is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxart is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxart has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Vaxart's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.35% of the outstanding shares of Vaxart have been sold short.Short Interest Ratio / Days to CoverVaxart has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Vaxart has recently decreased by 3.92%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVaxart does not currently pay a dividend.Dividend GrowthVaxart does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.35% of the outstanding shares of Vaxart have been sold short.Short Interest Ratio / Days to CoverVaxart has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Vaxart has recently decreased by 3.92%, indicating that investor sentiment is improving. News and Social Media3.1 / 5News Sentiment0.66 News SentimentVaxart has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Vaxart this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for VXRT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows11 people have added Vaxart to their MarketBeat watchlist in the last 30 days. This is an increase of 57% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vaxart insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.60% of the stock of Vaxart is held by insiders.Percentage Held by InstitutionsOnly 18.05% of the stock of Vaxart is held by institutions.Read more about Vaxart's insider trading history. Receive VXRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxart and its competitors with MarketBeat's FREE daily newsletter. Email Address VXRT Stock News HeadlinesVaxart, Inc. (VXRT) Q3 2024 Earnings Call TranscriptNovember 13 at 7:12 PM | seekingalpha.comVaxart Provides Business Update and Reports Third Quarter 2024 Financial ResultsNovember 13 at 4:01 PM | globenewswire.comHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.November 14, 2024 | Insiders Exposed (Ad)Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13November 7, 2024 | markets.businessinsider.comComparing Black Diamond Therapeutics (NASDAQ:BDTX) and Vaxart (NASDAQ:VXRT)November 6, 2024 | americanbankingnews.comVaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024October 24, 2024 | markets.businessinsider.comVaxart will present research on COVID-19, norovirus vaccine candidatesOctober 24, 2024 | markets.businessinsider.comOppenheimer Sticks to Their Buy Rating for Vaxart (VXRT)October 3, 2024 | markets.businessinsider.comSee More Headlines VXRT Stock Analysis - Frequently Asked Questions How have VXRT shares performed this year? Vaxart's stock was trading at $0.5728 at the start of the year. Since then, VXRT stock has increased by 24.7% and is now trading at $0.7143. View the best growth stocks for 2024 here. How were Vaxart's earnings last quarter? Vaxart, Inc. (NASDAQ:VXRT) announced its earnings results on Thursday, August, 8th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by $0.12. The biotechnology company earned $6.40 million during the quarter, compared to the consensus estimate of $65.70 million. Vaxart had a negative trailing twelve-month return on equity of 114.19% and a negative net margin of 543.21%. When did Vaxart's stock split? Vaxart shares reverse split on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. Who are Vaxart's major shareholders? Vaxart's top institutional shareholders include Mesirow Financial Investment Management Inc. (0.02%). Insiders that own company stock include W Mark Watson, Fuad Ahmad, Robert A Yedid and Margaret Echerd. View institutional ownership trends. How do I buy shares of Vaxart? Shares of VXRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Vaxart own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxart investors own include Plug Power (PLUG), Workhorse Group (WKHS), FuelCell Energy (FCEL), Fortress Biotech (FBIO), Assertio (ASRT), Ovid Therapeutics (OVID) and KALA BIO (KALA). Company Calendar Last Earnings8/08/2024Today11/13/2024Next Earnings (Confirmed)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VXRT Previous SymbolNASDAQ:NABI CUSIPN/A CIK72444 Webwww.vaxart.com Phone(650) 550-3500Fax650-871-8580Employees109Year Founded2004Price Target and Rating Average Stock Price Target$3.00 High Stock Price Target$4.00 Low Stock Price Target$2.00 Potential Upside/Downside+333.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,460,000.00 Net Margins-543.21% Pretax Margin-541.21% Return on Equity-114.19% Return on Assets-75.68% Debt Debt-to-Equity RatioN/A Current Ratio4.54 Quick Ratio4.54 Sales & Book Value Annual Sales$7.38 million Price / Sales16.63 Cash FlowN/A Price / Cash FlowN/A Book Value$0.38 per share Price / Book1.82Miscellaneous Outstanding Shares177,430,000Free Float172,812,000Market Cap$122.73 million OptionableOptionable Beta0.70 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NASDAQ:VXRT) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersWhat are you hiding Elon?? (Tesla’s secret 69% dividend)Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxart With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.